CAU
SLNO

Caxton Associates (UK)’s Soleno Therapeutics SLNO Stock Holding History

Caxton Associates (UK)’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,959
Closed -$230K – 988
2025
Q4 		$230K Buy
+4,959
New +$272K ﹤0.01% 683

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Caxton Associates (UK)'s SLNO Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 4,959 shares — an estimated $230K sold.

Caxton Associates (UK) first reported a position in SLNO in Q4 2025 and held it in 1 quarter. The position peaked at $230K in Q4 2025. 226 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Caxton Associates (UK) reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 4,959 Soleno Therapeutics shares in Q1 2026, an estimated $230K.
  • Caxton Associates (UK) first reported a position in Soleno Therapeutics in Q4 2025 and held it in 1 quarter.
  • Caxton Associates (UK)'s Soleno Therapeutics position peaked at $230K in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.